- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- EQR
- Stock Information
- Founded
- WST 1923
- EQR 1993
- Country
- WST United States
- EQR United States
- Employees
- WST N/A
- EQR N/A
- Industry
- WST Medical/Dental Instruments
- EQR Real Estate Investment Trusts
- Sector
- WST Health Care
- EQR Real Estate
- Exchange
- WST Nasdaq
- EQR Nasdaq
- Market Cap
- WST 15.6B
- EQR 26.7B
- IPO Year
- WST N/A
- EQR 1993
- Fundamental
- Price
- WST $222.00
- EQR $66.26
- Analyst Decision
- WST Buy
- EQR Buy
- Analyst Count
- WST 7
- EQR 15
- Target Price
- WST $331.67
- EQR $79.00
- AVG Volume (30 Days)
- WST 696.4K
- EQR 2.0M
- Earning Date
- WST 07-24-2025
- EQR 07-28-2025
- Dividend Yield
- WST 0.38%
- EQR 4.14%
- EPS Growth
- WST N/A
- EQR 8.50
- EPS
- WST 6.37
- EQR 2.62
- Revenue
- WST $2,895,800,000.00
- EQR $3,010,100,000.00
- Revenue This Year
- WST $3.38
- EQR $5.13
- Revenue Next Year
- WST $5.85
- EQR $4.28
- P/E Ratio
- WST $34.87
- EQR $25.56
- Revenue Growth
- WST N/A
- EQR 3.81
- 52 Week Low
- WST $187.43
- EQR $59.41
- 52 Week High
- WST $352.33
- EQR $78.84
- Technical
- Relative Strength Index (RSI)
- WST 55.47
- EQR 43.05
- Support Level
- WST $215.67
- EQR $65.87
- Resistance Level
- WST $226.80
- EQR $68.09
- Average True Range (ATR)
- WST 5.26
- EQR 1.32
- MACD
- WST -0.05
- EQR -0.14
- Stochastic Oscillator
- WST 65.84
- EQR 38.63
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.